Copyright
©The Author(s) 2023.
World J Virol. Dec 25, 2023; 12(5): 272-285
Published online Dec 25, 2023. doi: 10.5501/wjv.v12.i5.272
Published online Dec 25, 2023. doi: 10.5501/wjv.v12.i5.272
Table 1 Evaluation of clinical features in different groups of asthma patients
Others1 (n = 169) | Vaccinated patients (n = 57) | Atopic patients (n = 64) | P value | ES | |
Gender (male) | 128/169 (47.6) | 26/57 (45.6) | 38/64 (59.4) | 0.199 | 0.091 |
Fever | 100/163 (61.3) | 27/57 (47.4) | 40/63 (63.5) | 0.130 | 0.120 |
Fatigue | 60/163 (36.8) | 27/57 (47.4) | 24/63 (38.1) | 0.365 | 0.084 |
Headache | 51/163 (31.3) | 23/57 (40.4) | 22/63 (34.9) | 0.453 | 0.075 |
Muscle pain | 62/163 (38) | 17/57 (29.8) | 18/63 (28.6) | 0.296 | 0.093 |
Cough | 53/163 (32.5) | 24/57 (42.1) | 17/63 (27) | 0.205 | 0.106 |
Sore throat | 41/163 (25.2) | 15/57 (26.3) | 10/63 (15.9) | 0.280 | 0.095 |
Joint pain | 43/163 (26.4) | 11/57 (19.3) | 13/63 (20.6) | 0.452 | 0.075 |
Shortness of breath | 23/163 (14.1) | 17/57 (29.8) | 14/63 (22.2) | 0.026 | 0.160 |
Runny nose | 19/163 (11.7) | 5/57 (8.8) | 5/63 (7.9) | 0.653 | 0.055 |
Nausea | 15/163 (9.2) | 5/57 (8.8) | 6/63 (9.5) | 0.990 | 0.008 |
Vomiting | 10/163 (6.1) | 4/57 (7) | 6/63 (9.5) | 0.660 | 0.053 |
Diarrhea | 9/163 (5.5) | 4/57 (7) | 2/63 (3.2) | 0.624 | 0.057 |
Loss of taste and smell | 6/163 (3.7) | 6/57 (10.5) | 3/63 (4.8) | 0.148 | 0.119 |
Intra-familial contamination | 59/164 (36) | 15/57 (26.3) | 31/64 (48.4) | 0.039 | 0.151 |
Table 2 Evaluation of therapeutic features in different groups of asthma patients
Others1 (n = 169) | Vaccinated patients (n = 57) | Atopic patients (n = 64) | P value | ES | |
Preventive/prophylactic asthma medication usage | 31/164 (18.9) | 9/57 (16.1) | 16/62 (25.8) | 0.372 | 0.084 |
Salbutamol usage | 34/164 (20.7) | 11/57 (19.6) | 20/63 (31.7) | 0.169 | 0.112 |
Prednol usage | 2/164 (1.2) | 1/57 (1.8) | 0/64 (0) | 0.619 | 0.059 |
Emergency service admission | 27/164 (16.5) | 8/57 (14) | 14/64 (21.9) | 0.485 | 0.071 |
Hospitalization | 7/164 (4.3) | 3/57 (5.3) | 4/64 (6.3) | 0.866 | 0.038 |
Table 3 Evaluation of various laboratory parameters in different groups of asthma patients
Others4, (n = 169) | Vaccinated patients, (n = 57) | Atopic patients, (n = 64) | P value | ES | ||||
n | mean ± SD | n | mean ± SD | n | mean ± SD | |||
Age | 269 | 16.57 ± 4.16a | 57 | 18.86 ± 3.43b | 64 | 15.77 ± 3.87a | < 0.0011,3 | 0.049 |
COVID-19 age | 269 | 14.71 ± 4.09a | 57 | 17.28 ± 3.55b | 64 | 13.83 ± 3.75a | < 0.0011,3 | 0.063 |
Hemoglobin | 68 | 13.13 ± 1.44 | 12 | 13.66 ± 1.57 | 17 | 12.96 ± 1.83 | 0.4561 | 0.017 |
Leucocyte | 67 | 6803.79 ± 2825.88 | 12 | 6162.5 ± 2173.43 | 17 | 7068.24 ± 4155.47 | 0.9032 | 0.007 |
Neutrophil | 67 | 4119.30 ± 2601.78 | 12 | 3563.33 ± 1721.86 | 17 | 3762.94 ± 2089.5 | 0.9202 | 0.008 |
Lymphocyte | 68 | 1861.94 ± 939.88 | 12 | 1924.17 ± 1008.59 | 17 | 2503.53 ± 2908.44 | 0.9152 | 0.027 |
Eosinophil | 67 | 141.91 ± 171.81 | 12 | 157 ± 149.52 | 17 | 146.29 ± 190.62 | 0.3272 | 0.001 |
Platelet | 68 | 245864.71 ± 74049.74 | 12 | 273750 ± 77324.73 | 17 | 232352.94 ± 66343.75 | 0.3682 | 0.024 |
CRP | 62 | 10.28 ± 20.13a | 8 | 7.84 ± 5.34a | 14 | 2.85 ± 2.41b | 0.0162,3 | 0.025 |
Sedimentation | 5 | 11 ± 7.52 | 2 | 5 ± 1.41 | - | - | ||
AST | 63 | 25.58 ± 11.28 | 12 | 22.92 ± 5.23 | 16 | 27.06 ± 12.68 | 0.8292 | 0.011 |
ALT | 63 | 19.13 ± 13.72 | 12 | 20.17 ± 14.83 | 16 | 20.06 ± 17.47 | 0.9082 | 0.001 |
Urea | 61 | 21.5 ± 6.2 | 12 | 21.35 ± 7.18 | 16 | 22.45 ± 6.81 | 0.7272 | 0.004 |
PT | 33 | 12.07 ± 1.24 | 4 | 11.65 ± 0.95 | 8 | 12.49 ± 1.25 | 0.5121 | 0.031 |
aPTT | 31 | 28.87 ± 3.4 | 4 | 28.53 ± 1.97 | 7 | 28.96 ± 2.17 | 0.9741 | 0.001 |
D-Dimer | 48 | 508.98 ± 953.33 | 9 | 334.78 ± 206.13 | 11 | 265.18 ± 128.16 | 0.6472 | 0.015 |
LDH | 47 | 243.44 ± 88.75 | 8 | 202.59 ± 54.89 | 12 | 225.16 ± 87.56 | 0.3122 | 0.027 |
Total IgE | 37 | 176.05 ± 252.36a | 2 | 174.5 ± 144.96a,b | 13 | 1127.04 ± 1325.03b | 0.0092,3 | 0.274 |
Table 4 Evaluation of pathologic laboratory parameters in different groups of our asthma patients
Others1, (n = 169) | Vaccinated patients (n = 57) | Atopic patients (n = 64) | P value | ES | |
Leukopenia (< 4000) | 8/67 (11.9) | 2/12 (16.7) | 4/17 (23.5) | 0.541 | 0.125 |
Leukocytosis (> 10000) | 11/67 (16.4) | 0/12 (0) | 1/17 (5.9) | 0.193 | 0.186 |
Neutropenia (< 1500) | 6/67 (9) | 1/12 (8.3) | 1/17 (5.9) | 1.000 | 0.042 |
Neutrophilia (> 7500) | 10/67 (14.9) | 0/12 (0) | 2/17 (11.8) | 0.447 | 0.147 |
Lymphopenia (< 1500) | 29/68 (42.6) | 5/12 (41.7) | 10/17 (58.8) | 0.470 | 0.125 |
Lymphocytosis (> 4000) | 3/68 (4.4) | 0/12 (0) | 2/17 (11.8) | 0.475 | 0.152 |
Eosinophilia (> 500) | 4/67 (6) | 1/12 (8.3) | 1/17 (5.9) | 1.000 | 0.033 |
Thrombocytopenia (< 150000) | 5/68 (7.4) | 0/12 (0) | 1/17 (5.9) | 0.832 | 0.099 |
Thrombocytosis (> 450000) | 1/68 (1.5) | 0/12 (0) | 0/17 (0) | 1.000 | 0.067 |
Elevated CRP (> 3) | 42/62 (67.7) | 7/8 (87.5) | 6/14 (42.9) | 0.090 | 0.245 |
Elevated sedimentation (> 20) | 1/5 (20) | 0/2 (0) | - | 1.000 | 0.258 |
Elevated AST (> 50) | 2/63 (3.2) | 0/12 (0) | 1/16 (6.3) | 1.000 | 0.097 |
Elevated ALT (> 50) | 3/63 (4.8) | 1/12 (8.3) | 1/16 (6.3) | 1.000 | 0.054 |
Elevated urea (> 45) | 0/61 | 0/12 | 0/16 | - | - |
Elevated PT (>13.2) | 3/33 (9.1) | 0/4 (0) | 2/8 (25) | 0.261 | 0.221 |
Elevated aPTT (> 33.5) | 2/31 (6.5) | 0/4 (0) | 0/7 (0) | 1.000 | 0.133 |
Elevated D-dimer (> 500) | 6/48 (12.5) | 1/9 (11.1) | 1/11 (9.1) | 1.000 | 0.039 |
Elevated LDH (> 248) | 15/47 (31.9) | 2/8 (25) | 4/12 (33.3) | 1.000 | 0.052 |
Elevated total IgE (> 150) | 10/37 (27) | 1/2 (50) | 9/13 (69.2) | 0.019 | 0.376 |
- Citation: Özata MC, Dikici Ü, Özdemir Ö. COVID-19 frequency and clinical course in children with asthma. World J Virol 2023; 12(5): 272-285
- URL: https://www.wjgnet.com/2220-3249/full/v12/i5/272.htm
- DOI: https://dx.doi.org/10.5501/wjv.v12.i5.272